Apoptosis-mimicking synthetic entities and use thereof in...

Details Apoptosis-mimicking synthetic entities and use thereof in... Apoptosis-mimicking synthetic entities and use thereof in...

2005-10-11

2005-10-11

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C514S885000

Reexamination Certificate

active

06953591

ABSTRACT:
Synthetic and semisynthetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger an apoptosis-like mechanism in the patient.

REFERENCES:
patent: 4595680 (1986-06-01), della Valle et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5770234 (1998-06-01), Gristina et al.
patent: 5948756 (1999-09-01), Barenholz et al.
patent: 6290987 (2001-09-01), Modi
patent: 6312719 (2001-11-01), Hope et al.
patent: 6630313 (2003-10-01), Fadok et al.
patent: 2063039 (1992-09-01), None
patent: 41 17 629 (1992-12-01), None
patent: 0 315 349 (1989-05-01), None
patent: 0 505 817 (1992-09-01), None
patent: WO 92/02226 (1992-02-01), None
patent: WO 95/23592 (1995-09-01), None
patent: WO 01/43750 (2001-06-01), None
patent: 01/66875 (2001-09-01), None
Van Noort et al. International Review of Cytology, 1998.
Monastra, et al. (1993). “Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination,”Neurology, 43:153-163.
Girolomoni, et al. (1993). “Phosphatidylserine Enhances the Ability of Epidermal Langerhans Cells to Induce Contact Hypersensitivity,”The journal of Immunology, 150:4236-4243.
Bruni, A., et al. “Pharmacological effects of phosphatidylserine liposomes.”Nature260: 331-333 (1976).
Cenacchi, T., et al. “Cognitive decline inthe elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.”Aging Clin. Exp. Res.5: 123-133 (1993).
Engel, R.R., et al. “Double-blind cross-over study of phosphatidylserine vs.placebo in patients with early dementia of the Alzheimer type.”Eur. Neuropsychopharmacology.2: 149-155 (1992).
Miller, D., et al. “Is variant angina the coronary manifestation of a generalized vasospastic disorder?”The New England Journal of Medicine.304 (13): 763-766 (1981).
Oussoren, C., et al. “Lymphatic uptake and biodistribution of liposomes after subutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose.”Biochimica et Biophysica Acta.1328: 261-272 (1997).
Scott, R.S., et al., “Phagocytosis and clearance of apoptotic cells is mediated by MER.”Nature.411: 207-211 (2001).
Aramaki, “Liposomes as Immunomodular—Inhibitory Effect of Liposomes on NO Production from Macrophases,”Biol. Pharm. Bull., 2000, pp. 1267-1274, vol. 23, No. 11.
Bennett et al., “Binding and Phagocytosis of Apoptotic Vascular Smooth Muscle Cells Is Mediated in Part by Exposure of Phosphatidyserine,”Circulation Research, 1995, pp. 1136-1142, vol. 77, No. 6.
Bliss et al., “A synaptic model of memory: long-term potentiation in the hippocampus,”Nature, 1993, pp. 31-39, vol. 361.
Daemen et al., “Different Intrahepatic Distribution of Phosphatidylglycerol and Phosphatidyserine Liposomes in teh Rat,”Hepatology, 1997, pp. 416-423, vol. 26, No. 2.
Delwaide et al., “Double-blind radomized controlled study of phosphatidylserine in senile demented patients,”Acta neurol. Scand., 1986, pp. 136-140, vol. 73.
Emoto et al., “Short Note—Exposure of Phosphatidylethanolamine on the Surface of Apoptotic Cells,”Experimental Cell Research, 1997, pp. 430-434, vol. 232.
Fadok et al., “Macrophages That Have Ingested Apoptotic Cells In Vitro Inhibit Proinflammatory Cytokine Production Through Autocrine/Paracrine Mechanisms Involving TGF-β, PGE2, and PAF,”J. Clin. Invest., 1998, pp. 890-898, vol. 101, No. 4.
Fadok et al., “Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages,”The Journal of Immunology, 1992, pp. 2207-2216, vol. 148, No. 7.
Fadok et al., “A receptor for phosphatidylserine-specific clearance of apoptotic cells,”Nature, 2000, pp. 85-90, vol. 405.
Fadok et al., “Loss of Phopholipid Asymmetry and Surface Exposure of Phosphatidylserine Is Required for Phagocytosis of Apoptotic Cells by Macrophages and Fibroblasts,”The Journal of Biological Chemistry, 2001, pp. 1071-1077, vol. 276, No. 2.
Griffin et al., “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease,”Proc. natl. Acad. Sci., 1989, pp. 76-11-7615, vol. 86.
Kerr et al., “Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics,”Br. J. Cancer, 1972, pp. 239-257, vol. 26.
Kornbluth, “The immunological potential of apoptotic debris produced by tumor cells and during HIV infection,”Immunology Letters, 1994, pp. 125-132, vol. 43.
Mogi et al., “Interleukin (IL)-1β, IL-2,IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease,”Neuroscience Letters, 1996, pp. 13-16, vol. 211.
Monastra et al., “Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination,”Neurology, 1993, pp. 153-163, vol. 43.
Murray et al., “Evidence That Increased Hippocampal Expression of the Cytokine Interleukin-1β Is a Common Trigger for Age—and Stress-Induced Impairments in Long-Term Potentiation,”The Journal of Neuroscience, 1998, pp. 2974-2981, vol. 18, No. 8.
Miyamoto et al., “Effects of Differently Composed Liposomes on Pulmonary Arterial Pressure in Sheep—Involvement of Pulmonary Intravascular Macrophages,”Nihon Kyobu Skikkan Gakkai Zasshi, 1991, pp. 1268-1274, vol. 10 [English language abstract].
Nässander et al., “Liposomes”,Biodegradable Polymers as Drug Delivery Systems(M. Chasin and R. Langer, eds.), Marcel Dekker Inc., New York 1990, pps. 261-338, Chapter 8.
Palatini et al., “Pharmacokinetic characterization of phosphatidylserine liposomes in the rat,”Br. J. Pharmacol., 1991, pp. 345-350, vol. 102.
Shiratsuchi et al., “Phosphatidylserine-Mediated Phagocytosis of Anticancer Drug-Treated Cells by Macrophages,”J. Biochem., 1999, pp. 1101-1106, vol. 26, No. 6.
Zanotti et al., “Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats,”Psychopharmacology, 1989, pp. 316-321, vol. 99.
Aramaki et al., “Inhibitory Effects of Negatively Charged Liposomes on Nitric Oxide Production from Macrophages Stimulated by LPS,”Biochemical Biophysical Research Communications, 1996, pp. 1-6, vol. 220.

Affiliated with

Also associated with

Rating

Apoptosis-mimicking synthetic entities and use thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apoptosis-mimicking synthetic entities and use thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptosis-mimicking synthetic entities and use thereof in... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3476171